| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Plus Therapeutics Inc (NASDAQ: PSTV)
PSTV Technical Analysis
5
| As on 9th Jun 2023 PSTV STOCK Price closed @ 3.27 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.72 & Strong Buy for SHORT-TERM with Stoploss of 1.03 we also expect STOCK to react on Following IMPORTANT LEVELS. |
PSTVSTOCK Price
| Open | 3.62 | Change | Price | % |
| High | 3.62 | 1 Day | -0.25 | -7.10 |
| Low | 3.22 | 1 Week | -0.75 | -18.66 |
| Close | 3.27 | 1 Month | 3.02 | 1208.00 |
| Volume | 24700 | 1 Year | 2.15 | 191.96 |
| 52 Week High 4.91 | 52 Week Low 0.23 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| PSTV Daily Charts |
PSTV Intraday Charts |
Whats New @ Bazaartrend |
PSTV Free Analysis |
|
|
PSTV Important Levels Intraday
| RESISTANCE | 4.04 |
| RESISTANCE | 3.79 |
| RESISTANCE | 3.64 |
| RESISTANCE | 3.49 |
| SUPPORT | 3.05 |
| SUPPORT | 2.90 |
| SUPPORT | 2.75 |
| SUPPORT | 2.50 |
PSTV Forecast May 2024
| 4th UP Forecast | 4.12 |
| 3rd UP Forecast | 3.85 |
| 2nd UP Forecast | 3.68 |
| 1st UP Forecast | 3.51 |
| 1st DOWN Forecast | 3.03 |
| 2nd DOWN Forecast | 2.86 |
| 3rd DOWN Forecast | 2.69 |
| 4th DOWN Forecast | 2.42 |
PSTV Weekly Forecast
| 4th UP Forecast | 5.52 |
| 3rd UP Forecast | 4.80 |
| 2nd UP Forecast | 4.35 |
| 1st UP Forecast | 3.91 |
| 1st DOWN Forecast | 2.63 |
| 2nd DOWN Forecast | 2.19 |
| 3rd DOWN Forecast | 1.74 |
| 4th DOWN Forecast | 1.02 |
PSTV Forecast2024
| 4th UP Forecast | 12.67 |
| 3rd UP Forecast | 9.66 |
| 2nd UP Forecast | 7.79 |
| 1st UP Forecast | 5.93 |
| 1st DOWN Forecast | 0.61 |
| 2nd DOWN Forecast | -1.25 |
| 3rd DOWN Forecast | -3.12 |
| 4th DOWN Forecast | -6.13 |
Plus Therapeutics Inc ( NASDAQ USA Symbol : PSTV )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
PSTV Business Profile
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium NanoLiposomes, a patented radiotherapy for patients with recurrent glioblastoma, which is in the Phase 1 dose-finding clinical trial. The company is also developing DocePLUS, a patented chemotherapy for patients with solid tumors that is in Phase 1 clinical trial; and DoxoPLUS, a generic chemotherapy for patients with ovarian cancer. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. Address: 4200 Marathon Boulevard, Austin, TX, United States, 78756
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service